CLINICAL_TRIALS
trial_result
· 2016-03-29
Clinical Trial Update: 68Ga-DOTATATE PET Scan in Neuroendocrine Cancer [Phase 2]
Summary
Results from a Phase 2 trial evaluating 68Ga-DOTATATE PET imaging in neuroendocrine carcinoma have been completed and results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Neuroendocrine Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2016-03-29